Following on from a successful year of growth in 2018, the Multiple Myeloma Hub (MM Hub) continues to disseminate the latest congress news and clinical updates in multiple myeloma (MM).
Guided by an international Steering Committee of world experts in MM, the MM Hub is a global online resource that provides vital information for treatment teams, run in collaboration with the European School of Haematology (ESH). With an ever-expanding social media presence, the aim of the MM Hub is to engage with the global community on all major social media platforms to impact real-world clinical practice.
The MM Hub is designed to deliver upon an unmet clinical need for targeted medical updates, to help treatment teams involved in MM care make informed therapeutic decisions.
The MM Hub showcases unbiased and credible evidence-based literature, drug approvals, case studies, international congress coverage and expert opinions, delivered by Scientific Education Support (SES).
SES love nothing more than building communities and networks to enhance the level of collective knowledge, using multichannel communications to disseminate medical advances.
The MM Hub would like to thank bronze supporter Amgen
and contributor GSK
for their continued support of the initiative. This year, the MM Hub is proud to announce Janssen Oncology, as a silver supporter of the MM Hub. Janssen Oncology envisions a world where cancer is a preventable, chronic or curable disease. To get there, they focus on developing solutions that prolong and improve patient lives.
For more information on the MM Hub, please visit: www.multiplemyelomahub.com. For media enquiries, or to explore collaboration opportunities, please contact: email@example.com.
Press release distributed by Pressat on behalf of Scientific Education Support (SES), on Friday 31 May, 2019. For more information subscribe and follow https://pressat.co.uk/